HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China's Rising Role in Global ADC Partnership Wave - Opportunities and Risks Behind the Gold Rush

Hangzhou Tigermed Consulting (3347HK)-Turning Point Emerge, Followed by Sharp Decline in Performance

Hangzhou Tigermed Consulting (3347.HK) 23H1 - Performance Inflection Point Has Not yet Arrived

WuXi AppTec (2359.HK/603259.CH) - How Bad Things Could Be?

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

Hangzhou Tigermed Consulting C / Equity Bottom-Up

<ul>
<li>In the Chinese pharmaceutical industry, stock selection strategies can be divided into "defensive" and "offensive". We need to combine the judgment of the cycle to choose a stock picking strategy.</li>
<li>Domestic innovative pharmaceutical companies have the opportunity to create a high gross-margin incremental market of over RMB1 trillion through successful internationalization, but we pointed out the logical flaw behind.</li>
<li>We analyzed the key points of <a href="https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-c" target="_blank" data-smartkarma-citation="entities:29212:1" rel="noopener">Hangzhou Tigermed Consulting (3347 HK)</a>. It seems insiders don’t have firm confidence in the prospects, so why should investors rush to buy the bottom?</li>
</ul>


In the Chinese pharmaceutical industry, stock selection strategies can be divided into "defensive" and "offensive". We need to combine the judgment of the cycle to choose a stock picking strategy.
Domestic innovative pharmaceutical companies have the opportunity to create a high gross-margin incremental market of over RMB1 trillion through successful internationalization, but we pointed out the logical flaw behind.
We analyzed the key points of Hangzhou Tigermed Consulting (3347 HK). It seems insiders don’t have firm confidence in the prospects, so why should investors rush to buy the bottom?


Hangzhou Tigermed Consulting (A) (300347 CH)

China Healthcare Weekly (Dec.25) - Stock Picking Strategy, Logic Flaws Behind a Good Story, Tigermed